Loading...
XNASPBYI
Market cap174mUSD
Jan 08, Last price  
3.55USD
1D
-5.08%
1Q
31.00%
Jan 2017
-88.44%
IPO
-72.69%
Name

Puma Biotechnology Inc

Chart & Performance

D1W1MN
XNAS:PBYI chart
P/E
8.07
P/S
0.74
EPS
0.44
Div Yield, %
0.00%
Shrs. gr., 5y
4.62%
Rev. gr., 5y
-1.26%
Revenues
236m
+3.35%
0000-281,0960000027,700,000251,000,000272,300,000225,100,000253,200,000228,000,000235,637,000
Net income
22m
+2,267.43%
-15,093,000-14,083-16,836-15,976-10,232,878-74,300,000-54,659,000-142,000,000-239,300,000-276,000,000-292,000,000-113,600,000-82,723,000-60,000,000-29,100,000912,00021,591,000
CFO
27m
P
-15,093,000-11,834-16,815-18,246-1,825,018-44,000,000-55,048,000-77,200,000-154,500,000-141,700,000-172,500,000-24,100,00022,400,000800,00020,700,000-15,800,00027,009,000
Earnings
Feb 26, 2025

Profile

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
URL
https://www.pumabiotechnology.com/
IPO date
Mar 21, 2012
Employees
192
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
235,637
3.35%
228,000
-9.95%
Cost of revenue
202,372
197,300
Unusual Expense (Income)
NOPBT
33,265
30,700
NOPBT Margin
14.12%
13.46%
Operating Taxes
1,083
500
Tax Rate
3.26%
1.63%
NOPAT
32,182
30,200
Net income
21,591
2,267.43%
912
-103.13%
Dividends
Dividend yield
Proceeds from repurchase of equity
12,500
BB yield
-6.58%
Debt
Debt current
43,597
4,140
Long-term debt
84,527
126,115
Deferred revenue
Other long-term liabilities
5,011
12,826
Net debt
32,185
51,464
Cash flow
Cash from operating activities
27,009
(15,800)
CAPEX
(7,000)
Cash from investing activities
(19,125)
7,100
Cash from financing activities
12,200
FCF
31,582
32,770
Balance
Cash
95,939
76,200
Long term investments
2,591
Excess cash
84,157
67,391
Stockholders' equity
(1,345,163)
(1,366,750)
Invested Capital
1,519,906
1,515,457
ROIC
2.12%
2.01%
ROCE
19.04%
20.64%
EV
Common stock shares outstanding
47,551
44,930
Price
4.33
2.36%
4.23
39.14%
Market cap
205,895
8.34%
190,054
53.84%
EV
238,080
241,518
EBITDA
44,784
39,620
EV/EBITDA
5.32
6.10
Interest
13,330
11,500
Interest/NOPBT
40.07%
37.46%